GET DAILY SIGNALSSpero Therapeutics (SPRO): Can the Stock Reach the $5 Analyst Target for a +339% Gain?
Key Takeaways
- The central price target of $5 is the arithmetic mean of two verified analyst price targets — HC Wainwright's $6 (Buy) and Evercore ISI's $4 (Hold).
- With the stock trading near $1.14, reaching $5 would require a roughly 339% advance — a very large move for any equity.
- The verified analyst target range is wide, from $4 to $6, reflecting a genuine split between bullish and cautious views.
- Supporting factors include the U.S. approval of Utebzi (tebipenem HBr), the first oral carbapenem antibiotic, and its partnership with GSK.
- Key risks include sharply declining revenue, ongoing net losses, a small market capitalization, and a clinical-stage pipeline with concentrated outcomes.
- For more detail, explore Major News, Today's Price Move, Forecast, and Earnings on Tickeron.
- For AI-driven market scanning across thousands of tickers, explore Tickeron's Trending AI Robots.
Analyst Price Targets and How They Shape My View
Spero Therapeutics, Inc. (SPRO) is a clinical-stage biopharmaceutical company focused on treatments for multi-drug-resistant bacterial infections and rare diseases. With only two current, attributable analyst targets, the central figure of $5 comes directly from averaging HC Wainwright's $6 Buy rating (raised in September 2026) and Evercore ISI's $4 Hold rating. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The spread from $4 to $6 highlights real differences in outlook. The higher target factors in potential from the oral carbapenem assets and GSK collaboration milestones, while the lower one accounts for limited late-stage pipeline breadth and continued net losses. No major consensus aggregator lists this exact midpoint, so I treat it as a calculated reference point rather than an official Street average.
Where SPRO Stands Today and the Scale of the Required Move
At roughly $1.14, the $5 target implies a gain of about 339%. That is a substantial re-rating for a company whose market cap sits in the tens of millions. Reaching it would depend on execution around the Utebzi launch and related economics rather than sentiment alone. Revenue has already been declining, and forecasts point to further contraction in 2026 as collaboration terms evolve.
Factors That Could Help Close the Gap
The U.S. approval of Utebzi as the first oral carbapenem for complicated urinary tract infections stands out as the clearest positive. The GSK partnership shifts much of the commercial responsibility away from Spero, while candidates such as SP001 and SPR720 add longer-term optionality. A clean balance sheet with minimal debt also reduces immediate dilution pressure and supports continued development.
Risks That Could Keep the Target Out of Reach
Persistent net losses and negative EPS estimates remain headwinds. The concentrated pipeline means any single setback carries outsized impact. Thin analyst coverage and a wide target range leave little consensus to support a sustained re-rating. Milestone delays or disappointing launch metrics could weigh on the shares, and the stock’s beta near 1.5 adds extra volatility relative to the broader market.
Technical Context and Levels to Watch
Over the past year, SPRO has ranged from a low near $0.51 to a high around $3.22. The current price sits toward the lower end of that band. The $1 area offers psychological support, while reclaiming levels above $3 would mark the first significant resistance on any path toward $4 or $5.
Catalysts and Time Horizon
Analyst targets generally look out about 12 months. The key items to monitor are the GSK-led Utebzi launch progress, milestone and royalty payments, data updates for the earlier-stage programs, and any shifts in analyst views. Quarterly results and guidance will provide the clearest signals on whether the underlying thesis is holding.
Integrating AI Signals Into Research
I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry. For ongoing monitoring of a thinly covered name like SPRO, automated tools help surface changes that might otherwise be missed in fundamental work alone.
Using Tickeron AI Daily Buy/Sell Signals for Perspective
Tickeron's AI Daily Buy/Sell Signals apply artificial intelligence to scan thousands of stocks and ETFs, producing Buy, Sell, or Hold signals based on evolving technical patterns and market conditions. The system looks beyond single indicators to identify momentum shifts that can complement traditional analysis. For a volatile, lightly followed stock such as SPRO, these signals offer an additional layer of context when tracking launch execution and clinical developments.
Final Assessment
The $5 central target, derived from the $4 and $6 analyst figures, points to a roughly 339% advance from near $1.14. That outcome hinges on successful commercialization of Utebzi through the GSK partnership and positive pipeline progress, offset by risks around revenue contraction, ongoing losses, and concentrated clinical exposure. With only two attributable targets spanning a wide range, I focus on execution milestones and data readouts as the variables most likely to determine whether the stock can close the valuation gap.
Promo Section
In my own research process, Tickeron's AI Daily Buy/Sell Signals have become a regular part of reviewing names like SPRO. The tool scans thousands of tickers for shifting trends and momentum patterns, helping me cross-check fundamental views with technical signals without replacing them. It is one more data point I consult when weighing analyst targets against real-time market behavior.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
SPRO's Stochastic Oscillator descending into oversold zone
The Stochastic Oscillator for SPRO moved into oversold territory on October 26, 2026. Be on the watch for the price uptrend or consolidation in the future. At that time, consider buying the stock or exploring call options.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +10.91% 3-day Advance, the price is estimated to grow further. Considering data from situations where SPRO advanced for three days, in 151 of 206 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.
Bearish Trend Analysis
The 10-day RSI Indicator for SPRO moved out of overbought territory on September 23, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 27 similar instances where the indicator moved out of overbought territory. In 24 of the 27 cases, the stock moved lower in the following days. This puts the odds of a move lower at 89%.
The Momentum Indicator moved below the 0 level on October 22, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SPRO as a result. In 77 of 87 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.
The Moving Average Convergence Divergence Histogram (MACD) for SPRO turned negative on October 23, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 40 similar instances when the indicator turned negative. In 36 of the 40 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
SPRO moved below its 50-day moving average on October 21, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for SPRO crossed bearishly below the 50-day moving average on October 08, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 15 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SPRO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
SPRO broke above its upper Bollinger Band on September 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for SPRO entered a downward trend on October 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 48 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 78 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.502) is normal, around the industry mean (3.037). P/E Ratio (8.143) is within average values for comparable stocks, (-1.223). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.883) among similar stocks. P/S Ratio (1.550) is also within normal values, averaging (439.237).
The Tickeron Price Growth Rating for this company is 80 (best 1 - 100 worst), indicating slightly worse than average price growth. SPRO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 90 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SPRO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of novel therapies for the treatment of resistant bacterial infections
Industry Biotechnology
Advertisement